| Literature DB >> 35200627 |
Norma Flores-Holguín1, Joaquín Ortega-Castro2, Juan Frau2, Daniel Glossman-Mitnik1.
Abstract
As a continuation of our research on the chemical reactivity, pharmacokinetics and ADMET properties of cyclopeptides of marine origin with potential therapeutic abilities, in this work our already presented integrated molecular modeling protocol has been used for the study of the chemical reactivity and bioactivity properties of the Veraguamides A-G family of marine natural drugs. This protocol results from the estimation of the conceptual density functional theory (CDFT) chemical reactivity descriptors together with several chemoinformatics tools commonly considered within the process of development of new therapeutic drugs. CP-CDFT is a branch of computational chemistry and molecular modeling dedicated to the study of peptides, and it is a protocol that allows the estimation with great accuracy of the CDFT-based reactivity descriptors and the associated physical and chemical properties, which can aid in determining the ability of the studied peptides to behave as potential useful drugs. Moreover, the superiority of the MN12SX density functional over other long-range corrected density functionals for the prediction of chemical and physical properties in the presence of water as the solvent is clearly demonstrated. The research was supplemented with an investigation of the bioactivity of the molecular systems and their ADMET (absorption, distribution, metabolism, excretion, and toxicity) parameters, as is customary in medicinal chemistry. Some instances of the CDFT-based chemical reactivity descriptors' capacity to predict the pKas of peptides as well as their potential as AGE inhibitors are also shown.Entities:
Keywords: ADMET; KID (Koopmans In DFT); Veraguamides A–G; computational peptidology; computational pharmacokinetics; conceptual DFT
Mesh:
Substances:
Year: 2022 PMID: 35200627 PMCID: PMC8874632 DOI: 10.3390/md20020097
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Two-dimensional representations of the molecular structures of the Veraguamides A–G family of marine cyclic hexadepsipeptides.
Average GDK values of the seven members of the Veraguamides A–G family of marine peptides considering several density functionals and different common solvents.
| Solvent | 1/ | LC-BLYP | LC-PBE | MN12SX | CAM-B3LYP | LC- |
|---|---|---|---|---|---|---|
| NMF | 0.0055 | 4.17 | 4.16 | 0.02 | 2.15 | 3.88 |
| Formamide | 0.0092 | 4.18 | 4.17 | 0.02 | 2.16 | 3.89 |
| H2O | 0.0128 | 4.16 | 4.16 | 0.01 | 2.15 | 3.87 |
| Methanol | 0.0307 | 4.09 | 4.08 | 0.05 | 2.08 | 3.80 |
| Ethanol | 0.0402 | 4.00 | 3.99 | 0.11 | 2.00 | 3.81 |
| Acetone | 0.0488 | 3.73 | 3.72 | 0.27 | 1.77 | 3.45 |
| DCE | 0.0988 | 3.62 | 3.61 | 0.37 | 1.65 | 3.33 |
| THF | 0.1347 | 3.45 | 3.44 | 0.48 | 1.50 | 3.16 |
| DBE | 0.3282 | 2.95 | 2.94 | 0.85 | 1.03 | 2.67 |
| Cyclohexane | 0.4959 | 2.56 | 2.55 | 1.14 | 0.66 | 2.29 |
| n-Hexane | 0.5314 | 2.48 | 2.47 | 2.03 | 0.58 | 2.21 |
| Gas | 1.0000 | 1.36 | 1.35 | 2.08 | 0.48 | 1.09 |
|
|
|
|
|
|
|
|
| NMF | 0.0055 | 2.91 | 3.54 | 4.06 | 4.24 | 4.32 |
| Formamide | 0.0092 | 2.92 | 3.55 | 4.08 | 4.25 | 4.33 |
| H2O | 0.0128 | 2.90 | 3.53 | 4.06 | 4.23 | 4.32 |
| Methanol | 0.0307 | 2.84 | 3.46 | 3.99 | 4.16 | 4.24 |
| Ethanol | 0.0402 | 2.76 | 3.38 | 3.38 | 4.07 | 4.16 |
| Acetone | 0.0488 | 2.53 | 3.12 | 3.01 | 3.80 | 3.88 |
| DCE | 0.0988 | 2.42 | 3.01 | 2.89 | 3.68 | 3.77 |
| THF | 0.1347 | 2.26 | 2.84 | 2.72 | 3.51 | 3.59 |
| DBE | 0.3282 | 1.80 | 2.36 | 2.60 | 3.02 | 3.10 |
| Cyclohexane | 0.4959 | 1.43 | 1.98 | 2.47 | 2.63 | 2.71 |
| n-Hexane | 0.5314 | 1.35 | 1.90 | 2.39 | 2.55 | 2.63 |
| Gas | 1.0000 | 0.28 | 0.79 | 1.26 | 1.42 | 1.50 |
Figure 2Optimized molecular structures of Veraguamides A–G family of marine cyclic hexadepsipeptides.
Frontier orbital energies, H-L gap and the KID indices (all in eV) used for the verification of the ionization energy theorem behavior of the MN12SX density functional in the study of the chemical reactivity of the veraguamides A–G marine natural drugs.
| Molecule | HOMO | LUMO | SOMO | H-L Gap | J(I) | J(A) | J(HL) | |
|---|---|---|---|---|---|---|---|---|
| Veraguamide A | −6.635 | −0.884 | −0.892 | 5.751 | 0.006 | 0.003 | 0.006 | 0.003 |
| Veraguamide B | −6.637 | −0.942 | −0.912 | 5.695 | 0.008 | 0.012 | 0.014 | 0.030 |
| Veraguamide C | −6.812 | −0.993 | −0.946 | 5.819 | 0.003 | 0.017 | 0.017 | 0.048 |
| Veraguamide D | −6.661 | −0.748 | −0.759 | 5.913 | 0.010 | 0.005 | 0.011 | 0.011 |
| Veraguamide E | −6.873 | −0.717 | −0.702 | 6.156 | 0.002 | 0.007 | 0.007 | 0.014 |
| Veraguamide F | −6.717 | −1.016 | −0.972 | 5.702 | 0.002 | 0.015 | 0.015 | 0.019 |
| Veraguamide G | −6.697 | −0.771 | −0.768 | 5.926 | 0.009 | 0.001 | 0.009 | 0.003 |
Global reactivity descriptors for the veraguamides A–G family of marine cyclopeptides: Electronegativity (), Hardness (), Electrophilicity () (all in eV), Softness S (in ), Nucleophilicity N, Electrodonating Power (), Electroaccepting Power () and Net Electrophilicity () (also in eV).
| Molecule |
|
|
| S | N |
|
|
|
|---|---|---|---|---|---|---|---|---|
| Veraguamide A | 3.760 | 5.751 | 1.229 | 0.174 | 2.157 | 4.697 | 0.937 | 5.634 |
| Veraguamide B | 3.790 | 5.695 | 1.261 | 0.176 | 2.156 | 4.772 | 0.983 | 5.755 |
| Veraguamide C | 3.903 | 5.819 | 1.309 | 0.172 | 1.981 | 4.932 | 1.030 | 5.962 |
| Veraguamide D | 3.704 | 5.913 | 1.160 | 0.169 | 2.132 | 4.543 | 0.838 | 5.381 |
| Veraguamide E | 3.795 | 6.156 | 1.170 | 0.162 | 1.920 | 4.621 | 0.827 | 5.448 |
| Veraguamide F | 3.867 | 5.702 | 1.311 | 0.175 | 2.075 | 4.912 | 1.045 | 5.957 |
| Veraguamide G | 3.734 | 5.926 | 1.177 | 0.169 | 2.096 | 4.590 | 0.856 | 5.447 |
Figure 3Graphical representation of the dual descriptor DD of the Veraguamide A, Veraguamide B, Veraguamide C, Veraguamide D, Veraguamide E, Veraguamide F and Veraguamide G molecules. Left: DD > 0, Right: DD < 0.
Predicted pKas for the Veraguamides A–G family of marine cyclopeptides.
| Molecule | pKa |
|---|---|
| Veraguamide A | 12.36 |
| Veraguamide B | 12.40 |
| Veraguamide C | 12.55 |
| Veraguamide D | 12.58 |
| Veraguamide E | 12.60 |
| Veraguamide F | 12.50 |
| Veraguamide G | 12.62 |
Figure 4Bioavailability radars of the Veraguamide A, Veraguamide B, Veraguamide C, Veraguamide D, Veraguamide E, Veraguamide F and Veraguamide G molecules.
Bioactivity Scores of the veraguamides A–G.
| Molecule | GPCR | Ion Channel | Nuclear Receptor | Kinase | Protease | Enzyme |
|---|---|---|---|---|---|---|
| Ligand | Modulator | Ligand | Inhibitor | Inhibitor | Inhibitor | |
| Veraguamide A | −0.42 | −1.45 | −1.21 | −1.18 | 0.05 | −0.83 |
| Veraguamide B | −0.33 | −1.31 | −1.07 | −1.02 | 0.13 | −0.73 |
| Veraguamide C | −0.29 | −1.21 | −1.06 | −0.96 | 0.20 | −0.62 |
| Veraguamide D | −0.42 | −1.39 | −1.22 | −1.18 | 0.12 | −0.76 |
| Veraguamide E | −0.55 | −1.57 | −1.38 | −1.35 | 0.02 | −0.91 |
| Veraguamide F | −0.64 | −1.78 | −1.55 | −1.43 | −0.09 | −1.09 |
| Veraguamide G | −0.35 | −1.32 | −1.12 | −1.04 | 0.13 | −0.72 |
Computed ADMET Features of the Veraguamides A–G.
| Property | Veraguamides | ||||||
|---|---|---|---|---|---|---|---|
| A | B | C | D | E | F | G | |
| HI Absorption | + | + | + | + | + | + | + |
| BBB Permeability | + | + | + | + | + | + | + |
| Caco-2 | - | - | - | - | - | - | - |
| P-gp Substrate | + | + | + | + | + | + | + |
| P-gp Inhibitor | + | + | + | + | + | + | + |
| CYP2C9 Substrate | - | - | - | - | - | + | - |
| CYP2D6 Substrate | - | - | - | - | - | - | - |
| CYP3A4 Substrate | + | + | + | + | + | + | + |
| CYP1A2 Inhibitor | - | - | - | - | - | - | - |
| CYP2C19 Inhibitor | - | - | - | - | - | - | - |
| CYP2C9 Inhibitor | - | - | - | - | - | - | - |
| CYP2D6 Inhibitor | - | - | - | - | - | - | - |
| CYP3A4 Inhibitor | - | - | - | - | - | - | - |
| OCT2 Substrate | - | - | - | - | - | - | - |
| AMES Toxicity | - | - | - | - | - | - | - |
| hERG Inhibitor | - | - | - | - | - | - | - |
| Hepatotoxicity | + | + | + | + | + | + | + |
| Skin Sensitization | - | - | - | - | - | - | - |